Sentence examples for an efficacy analysis of from inspiring English sources

We conducted an efficacy analysis of the care provided at CRMM nested in a 6-month ambispective cohort of patients with MM who were receiving thalidomide treatment at CRMM-HCPA, from May 2012 to May 2014.

In an efficacy analysis of 94 patients (DZ, 48; D, 46), the median progression-free survival was 2.7 months (95% confidence interval [CI], 1.5 3.5 months) for the DZ group and 2.6 months (95% CI, 1.5 3.4 months) for the D group (stratified log-rank test, P = 0.89).

Consequently, an amendment to the study protocol was issued before unblinding, defining a secondary efficacy analysis of the primary endpoint that is, analysis of a binary endpoint (progression vs non-progression at 3 years) derived from the continuous JSN.

A pooled efficacy analysis of four randomized (1 1) and one non-comparative clinical trials of amoxicillin/clavulanate, 2000/125 mg, given twice daily, was conducted in adult patients with CAP.

A second exploratory efficacy analysis of OS included only patients who did not cross over to the other arm and thus predominantly comprised patients with nonresponsive disease.

However, a phase III clinical study evaluating the efficacy and safety of bevacizumab together with rituximab plus CHOP in patients with DLBCL (MAIN trial) could not be completed after a safety and efficacy analysis of the first 720 patients.

Numerous studies have used viral sequencing to evaluate HIV-1 transmission linkage, but our analysis represents the first use of viral sequencing for HIV-1 transmission linkage as an integral component in the primary efficacy analysis of a large randomized HIV-1 prevention trial.

45 A pooled safety and efficacy analysis of prospective colonic stenting studies encompassing around 1, 200 patients demonstrated median technical and clinical success rates of 94%and91%1%, respectively, with a stent-related mortality of 0.58%.

Over 40 000 subjects have been vaccinated in clinical trials of this vaccine, and a recent integrated safety and efficacy analysis of 11 trials showed that the vaccine was generally well tolerated in over 16 000 females (≥ 10 years old) who received at least one dose [10].

The formal efficacy analysis consisted of a set of analyses of covariance (ANCOVAs), one for each efficacy endpoint.

One patient in the FAS group was excluded from the efficacy analysis because of a problem in the maintenance of the blind.